BrainTransporter™ dramatically improves antibody delivery to the brain
Rhea-AI Summary
BioArctic AB has unveiled its proprietary BrainTransporter (BT) platform at the PEGS conference in Barcelona. The technology demonstrates up to 70-fold higher penetration of antibodies across the blood-brain barrier using Transferrin Receptor-mediated transport, without negative effects on hematological safety. The platform shows rapid, broad, and deep distribution of amyloid-beta antibodies across the brain in preclinical models. In April 2024, BioArctic and Eisai entered a research evaluation agreement for BAN2802, combining BT technology with an Alzheimer drug candidate.
Positive
- Technology achieves 70-fold increase in brain antibody delivery
- No negative effects on hematological safety parameters observed
- Existing partnership agreement with Eisai for BAN2802
- Multiple potential partnering opportunities across different therapy areas
Negative
- Technology still in preclinical stage
- No guaranteed success in clinical development or regulatory approval
Insights
The BrainTransporter platform represents a significant breakthrough in CNS drug delivery technology. The 70-fold increase in brain penetration for antibodies is unprecedented in the field and could revolutionize treatment approaches for neurological disorders. The technology's ability to leverage the natural TfR pathway while maintaining safety is particularly noteworthy.
The platform's versatility and demonstrated safety profile make it highly valuable for potential partnerships across multiple therapeutic areas. The existing agreement with Eisai, a major player in Alzheimer's treatment, validates the technology's commercial potential. This could lead to improved efficacy of existing CNS drugs and enable development of new therapeutics previously by poor brain penetration.
This technology positions BioArctic advantageously in the lucrative CNS therapeutics market. The partnership with Eisai demonstrates early commercial validation and the platform's broad applicability opens multiple revenue streams through potential licensing deals. The ability to improve existing drugs' efficacy while potentially reducing dosing requirements presents a compelling value proposition for both pharmaceutical partners and healthcare systems.
The market impact extends beyond Alzheimer's disease to other CNS disorders, representing a significant expansion of BioArctic's addressable market. The technology could become an essential platform for developing next-generation CNS therapeutics, potentially generating substantial licensing revenues.
During the 16th annual Protein & Antibody Engineering Summit (PEGS)
Brain uptake of biotherapeutics such as antibodies and enzymes is severely limited by the blood brain barrier (BBB) primarily due to their size. Active transport across the BBB, using one of the body's own delivery mechanisms, aims to enable better drug uptake into the brain. The BT technology utilizes the Transferrin Receptor (TfR), a protein facilitating transport across the BBB, to optimize brain delivery.
The PEGS summit presentation included results in preclinical models demonstrating up to 70-fold increase of amyloid-beta antibody brain exposure using the BT technology, with a rapid, broad and deep distribution of amyloid-beta antibodies across the brain. The results provide preclinical validation of a BT-linked amyloid-beta monoclonal antibody, without negative effects on hematological parameters including reticulocytes.
"I am excited that we now can present our excellent preclinical data with the BrainTransporter technology. This technology has huge potential to improve many therapies by helping more drug reach its target in the brain, and could thereby in the future offer patients with different brain disorders new treatment opportunities," said Gunilla Osswald, CEO at BioArctic. "The technology has the potential to create faster and improved efficacy of treatments targeted to the brain with less side effects and lower doses for the benefit of both patients and society."
The BT technology could be used in a number of different therapy areas, giving BioArctic many potential future partnering opportunities. A first agreement with the BT-technology was signed in April 2024, when BioArctic AB and Eisai Co., Ltd., entered into a research evaluation agreement regarding BAN2802, a potential new treatment combining BioArctic's proprietary BrainTransporter technology with an undisclosed Alzheimer drug candidate.
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.
The information was released for public disclosure, through the agency of the contact person above, at 3.00 p.m. CET on November 6, 2024.
For more information, please contact:
Oskar Bosson, Vice President Communications and Investor Relations
Telephone: + 46 70 410 71 80
E-mail: oskar.bosson@bioarctic.com
About the BrainTransporter technology
BioArctic's BrainTransporter technology is a technology for facilitating the passage of biological drugs as for example antibodies into the brain using the transferrin receptor (TfR). Active transport of biotherapeutics across the blood brain barrier can result in broader brain distribution enabling better efficacy, improved safety profile and dosing convenience. The technology is being applied to several in-house drug projects and could become part of future collaborations with other pharma companies.
About BioArctic
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
BrainTransporterâ„¢ dramatically improves antibody delivery to the brain | |
https://news.cision.com/bioarctic/i/antibody-dirstribution-with-and-without-bt-technology,c3349392 | Antibody dirstribution with and without BT technology |
View original content:https://www.prnewswire.com/news-releases/braintransporter-dramatically-improves-antibody-delivery-to-the-brain-302297555.html
SOURCE BioArctic
FAQ
What is the brain penetration improvement achieved by BioArctic's BrainTransporter platform?
When did BioArctic (BIOA B) sign its first BrainTransporter technology agreement with Eisai?
How does BioArctic's BrainTransporter technology work?
